The two selected speakers, who are experts in myositis therapeutic trials, will review new biologic and drug therapies for adult and juvenile myositis, including results of recently completed therapeutic trials, the rationale for their use, and consensus approaches to the treatment of juvenile dermatomyositis. Traditional therapies consisting of corticosteroids and immunosuppressive agents, while commonly used in patients with inflammatory myopathies, often have not been studied in clinical trials. Further, patients may be refractory to these treatments. As the result of initiatives to understand best traditional treatments and several recently completed clinical trials of biologic therapies in patients with refractory myositis, managing physicians now have considerable therapeutic options for these patients, which will be reviewed in this session.
Upon completion of this session, participants should be able to:
- explain the results of biologic therapeutic trials (rituximab, anti-TNF agents, anakinra) for adult dermatomyositis and polymyositis
- determine the rationale behind biologic therapies for the treatment of myositis and to discuss their clinical efficacy
- report the results of recently completed therapeutic trials for juvenile dermatomyositis
- review the consensus driven treatment approaches from PRINTO and CARRA
To see other sessions for this day, use the date buttons to the left.